Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 793 to 797 of 797 entries
Sorted by: Best Match Show Resources per page
Charcot-Marie-tooth disease causing mutation (p.R158H) in pyruvate dehydrogenase kinase 3 (PDK3) affects synaptic transmission, ATP production and causes neurodegeneration in a CMTX6 C. elegans model.

Human molecular genetics

Narayanan RK, Brewer MH, Perez-Siles G, Ellis M, Ly C, Burgess A, Neumann B, Nicholson GA, Vucic S, Kennerson ML.
PMID: 34387338
Hum Mol Genet. 2021 Dec 17;31(1):133-145. doi: 10.1093/hmg/ddab228.

Charcot-Marie-Tooth (CMT) is a commonly inherited, non-fatal neurodegenerative disorder that affects sensory and motor neurons in patients. More than 90 genes are known to cause axonal and demyelinating forms of CMT. The p.R158H mutation in the pyruvate dehydrogenase kinase...

Cite
Narayanan RK, Brewer MH, Perez-Siles G, et al. Charcot-Marie-tooth disease causing mutation (p.R158H) in pyruvate dehydrogenase kinase 3 (PDK3) affects synaptic transmission, ATP production and causes neurodegeneration in a CMTX6 C. elegans model. Hum Mol Genet. 2021;31(1):133-145doi: 10.1093/hmg/ddab228.
Narayanan, R. K., Brewer, M. H., Perez-Siles, G., Ellis, M., Ly, C., Burgess, A., Neumann, B., Nicholson, G. A., Vucic, S., & Kennerson, M. L. (2021). Charcot-Marie-tooth disease causing mutation (p.R158H) in pyruvate dehydrogenase kinase 3 (PDK3) affects synaptic transmission, ATP production and causes neurodegeneration in a CMTX6 C. elegans model. Human molecular genetics, 31(1), 133-145. https://doi.org/10.1093/hmg/ddab228
Narayanan, Ramesh K, et al. "Charcot-Marie-tooth disease causing mutation (p.R158H) in pyruvate dehydrogenase kinase 3 (PDK3) affects synaptic transmission, ATP production and causes neurodegeneration in a CMTX6 C. elegans model." Human molecular genetics vol. 31,1 (2021): 133-145. doi: https://doi.org/10.1093/hmg/ddab228
Narayanan RK, Brewer MH, Perez-Siles G, Ellis M, Ly C, Burgess A, Neumann B, Nicholson GA, Vucic S, Kennerson ML. Charcot-Marie-tooth disease causing mutation (p.R158H) in pyruvate dehydrogenase kinase 3 (PDK3) affects synaptic transmission, ATP production and causes neurodegeneration in a CMTX6 C. elegans model. Hum Mol Genet. 2021 Dec 17;31(1):133-145. doi: 10.1093/hmg/ddab228. PMID: 34387338.
Copy Download .nbib Format: NLM
Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes.

The journal of pain

Ellis MS, Kasper Z, Cicero T.
PMID: 33197581
J Pain. 2021 Apr;22(4):432-439. doi: 10.1016/j.jpain.2020.10.005. Epub 2020 Nov 14.

Chronic pain is a significant comorbid condition among individuals with opioid use disorder (OUD). However, due to conflicting perceptions of responsibility, structural barriers, and a lack of widely applied standards of care, it is unclear what the landscape of...

Cite
Ellis MS, Kasper Z, Cicero T. Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes. J Pain. 2020;22(4):432-439doi: 10.1016/j.jpain.2020.10.005.
Ellis, M. S., Kasper, Z., & Cicero, T. (2021). Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes. The journal of pain, 22(4), 432-439. https://doi.org/10.1016/j.jpain.2020.10.005
Ellis, Matthew S, et al. "Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes." The journal of pain vol. 22,4 (2021): 432-439. doi: https://doi.org/10.1016/j.jpain.2020.10.005
Ellis MS, Kasper Z, Cicero T. Assessment of Chronic Pain Management in the Treatment of Opioid Use Disorder: Gaps in Care and Implications for Treatment Outcomes. J Pain. 2021 Apr;22(4):432-439. doi: 10.1016/j.jpain.2020.10.005. Epub 2020 Nov 14. PMID: 33197581.
Copy Download .nbib Format: NLM
How Are Families Faring? Perceived Family Functioning Among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers.

Journal of adolescent and young adult oncology

Kamaladasa DS, Sansom-Daly UM, Hetherington K, McGill BC, Ellis SJ, Kelada L, Donoghoe MW, Evans H, Anazodo A, Patterson P, Cohn RJ, Wakefield CE.
PMID: 33960837
J Adolesc Young Adult Oncol. 2021 Dec;10(6):711-719. doi: 10.1089/jayao.2020.0215. Epub 2021 May 06.

No abstract available.

Cite
Kamaladasa DS, Sansom-Daly UM, Hetherington K, et al. How Are Families Faring? Perceived Family Functioning Among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers. J Adolesc Young Adult Oncol. 2021;10(6):711-719doi: 10.1089/jayao.2020.0215.
Kamaladasa, D. S., Sansom-Daly, U. M., Hetherington, K., McGill, B. C., Ellis, S. J., Kelada, L., Donoghoe, M. W., Evans, H., Anazodo, A., Patterson, P., Cohn, R. J., & Wakefield, C. E. (2021). How Are Families Faring? Perceived Family Functioning Among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers. Journal of adolescent and young adult oncology, 10(6), 711-719. https://doi.org/10.1089/jayao.2020.0215
Kamaladasa, Dinuli S, et al. "How Are Families Faring? Perceived Family Functioning Among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers." Journal of adolescent and young adult oncology vol. 10,6 (2021): 711-719. doi: https://doi.org/10.1089/jayao.2020.0215
Kamaladasa DS, Sansom-Daly UM, Hetherington K, McGill BC, Ellis SJ, Kelada L, Donoghoe MW, Evans H, Anazodo A, Patterson P, Cohn RJ, Wakefield CE. How Are Families Faring? Perceived Family Functioning Among Adolescent and Young Adult Cancer Survivors in Comparison to Their Peers. J Adolesc Young Adult Oncol. 2021 Dec;10(6):711-719. doi: 10.1089/jayao.2020.0215. Epub 2021 May 06. PMID: 33960837.
Copy Download .nbib Format: NLM
Toward a fine-scale population health monitoring system.

Cell

Belbin GM, Cullina S, Wenric S, Soper ER, Glicksberg BS, Torre D, Moscati A, Wojcik GL, Shemirani R, Beckmann ND, Cohain A, Sorokin EP, Park DS, Ambite JL, Ellis S, Auton A, Bottinger EP, Cho JH, Loos RJF, Abul-Husn NS, Zaitlen NA, Gignoux CR, Kenny EE.
PMID: 33861964
Cell. 2021 Apr 15;184(8):2068-2083.e11. doi: 10.1016/j.cell.2021.03.034.

Understanding population health disparities is an essential component of equitable precision health efforts. Epidemiology research often relies on definitions of race and ethnicity, but these population labels may not adequately capture disease burdens and environmental factors impacting specific sub-populations....

Cite
Belbin GM, Cullina S, Wenric S, et al. Toward a fine-scale population health monitoring system. Cell. 2021;184(8):2068-2083.e11doi: 10.1016/j.cell.2021.03.034.
Belbin, G. M., Cullina, S., Wenric, S., Soper, E. R., Glicksberg, B. S., Torre, D., Moscati, A., Wojcik, G. L., Shemirani, R., Beckmann, N. D., Cohain, A., Sorokin, E. P., Park, D. S., Ambite, J. L., Ellis, S., Auton, A., Bottinger, E. P., Cho, J. H., Loos, R. J. F., Abul-Husn, N. S., Zaitlen, N. A., Gignoux, C. R., & Kenny, E. E. (2021). Toward a fine-scale population health monitoring system. Cell, 184(8), 2068-2083.e11. https://doi.org/10.1016/j.cell.2021.03.034
Belbin, Gillian M, et al. "Toward a fine-scale population health monitoring system." Cell vol. 184,8 (2021): 2068-2083.e11. doi: https://doi.org/10.1016/j.cell.2021.03.034
Belbin GM, Cullina S, Wenric S, Soper ER, Glicksberg BS, Torre D, Moscati A, Wojcik GL, Shemirani R, Beckmann ND, Cohain A, Sorokin EP, Park DS, Ambite JL, Ellis S, Auton A, Bottinger EP, Cho JH, Loos RJF, Abul-Husn NS, Zaitlen NA, Gignoux CR, Kenny EE. Toward a fine-scale population health monitoring system. Cell. 2021 Apr 15;184(8):2068-2083.e11. doi: 10.1016/j.cell.2021.03.034. PMID: 33861964.
Copy Download .nbib Format: NLM
VO.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, Tian S, Harris RA, Kotsimbos T, Keating D.
PMID: 33358691
J Cyst Fibros. 2021 May;20(3):499-505. doi: 10.1016/j.jcf.2020.12.006. Epub 2020 Dec 24.

BACKGROUND: The impact of lumacaftor/ivacaftor on exercise tolerance in people with cystic fibrosis (CF) has not been thoroughly studied.METHODS: We conducted a multisite Phase 4 trial comparing the impact of lumacaftor/ivacaftor on exercise tolerance with that of placebo in...

Cite
Wilson J, You X, Ellis M, et al. VO. J Cyst Fibros. 2020;20(3):499-505doi: 10.1016/j.jcf.2020.12.006.
Wilson, J., You, X., Ellis, M., Urquhart, D. S., Jha, L., Duncan, M., Tian, S., Harris, R. A., Kotsimbos, T., & Keating, D. (2021). VO. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 20(3), 499-505. https://doi.org/10.1016/j.jcf.2020.12.006
Wilson, John, et al. "VO." Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society vol. 20,3 (2021): 499-505. doi: https://doi.org/10.1016/j.jcf.2020.12.006
Wilson J, You X, Ellis M, Urquhart DS, Jha L, Duncan M, Tian S, Harris RA, Kotsimbos T, Keating D. VO. J Cyst Fibros. 2021 May;20(3):499-505. doi: 10.1016/j.jcf.2020.12.006. Epub 2020 Dec 24. PMID: 33358691.
Copy Download .nbib Format: NLM
Showing 793 to 797 of 797 entries